卡左双多巴控释片对帕金森病合并睡眠障碍患者认知障碍及日常生活能力的影响

Effects of Carzodopa Controlled Release Tablets on Cognitive Impairment and Activities of Daily Living in Patients with Parkinson's Disease and Sleep Disorders

目的讨论卡左双多巴控释片对帕金森病合并睡眠障碍患者的临床应用,分析对其认知障碍及日常生活能力的影响。方法方便选取2020年12月—2021年8月该院收治的62例帕金森病合并睡眠障碍患者为研究对象,按照双盲分组法划分为两个组别,分别为参照组与治疗组,每组31例。给予参照组患者艾司唑仑进行治疗,治疗组患者应用的治疗措施则为卡左双多巴控释片,观察两组患者不同药物作用下病症改善效果及对生活能力的影响。结果治疗组治疗7 d后其认知能力及生活能力评分分别为(17.93±2.11)分、(69.21±4.33)分,治疗15 d后其认知能力及生活能力评分分别为(18.89±1.23)分、(77.33±3.78)分,各项数据均显著优于参照组,差异有统计学意义(t=2.764、6.136、3.606、9.055,P<0.05)。治疗组不良反应发生率3.22%低于参照组,差异有统计学意义(χ^(2)=7.631,P<0.05)。结论对帕金森病合并睡眠障碍患者施以卡左双多巴控释片进行治疗,可显著修复患者认知功能障碍,对提升患者生活能力有着积极作用,治疗效果优异,临床应用价值高。

Objective To discuss the clinical application of Carzodopa controlled-release tablets in patients with Parkinson's disease and sleep disorders,and to analyze the impact on cognitive impairment and daily living ability.Methods 62 patients with Parkinson's disease complicated with sleep disorder treated in the hospital from December 2020 to August 2021 were conveniently selected as the research object.According to the double-blind grouping method,they were divided into two groups:reference group and treatment group,with 31 cases in each group,estazolam was given to patients in the reference group for treatment,and the treatment for patients in the treatment group was carvodopa controlled-release tablets.The two groups of patients were observed of the effect of improving the disease and the impact on living ability under the action of different drugs.Results The scores of cognitive ability and living ability in the treatment group were(17.93±2.11)points and(69.21±4.33)points,respectively,after 7 days of treatment;and(18.89±1.23)points and(77.33±3.78)points,respectively,after 15 days of treatment.All the data were significantly better than those in the reference group,the difference were statistically significant(t=2.764,6.136,3.606,9.055,P<0.05).The incidence of adverse reactions in the treatment group(3.21%)was lower than that in the reference group,the difference was statistically significant(χ^(2)=7.631,P<0.05).Conclusion Carzodopa controlled-release tablets for patients with Parkinson's disease and sleep disorders can significantly repair the cognitive dysfunction of the patients,and have a positive effect on improving the life ability of the patients.The treatment effect is excellent and the clinical application value is high.